Two halves, two stories – the healthcare sector 2025 annual recap
2025 has been a year defined by two distinct narratives for the healthcare sector. During the first half of the year, attention was heavily focused on political uncertainty and the presence of unknown factors. In contrast, the second half of the year has seen a shift in focus toward established Most Favored Nation (MFN) deals […]
Monthly comment (November 2025): Continued momentum for the healthcare sector
The healthcare sector had continued momentum in November, with focus shifting from political uncertainty to underlying fundamentals. Another strong month for the fund which saw positive contributions from all sub-sectors, with biotechnology making the strongest contribution. The fund benefited from the acquisition of Exact Sciences by Abbott. While the outlook for the sector overall looks […]
Investeringschef Henrik Rhenman gästar Direkt med Förvaltarna
Rhenman & Partners investeringschef Henrik Rhenman deltar i Direkt med förvaltarna där han samtalar med programledare Eric Lindeen om läget i hälsovårdssektorn och om fonden. Eric och Henrik diskuterar bland annat innovationen och tillväxten i sektorn, Henrik delar dessutom sin syn på vikten av små- och medelstora bolag i fonden. Hela avsnittet går att […]
Monthly comment (October 2025): Earnings season off to a strong start
Summary Strong start to the earnings season for the healthcare sector, supported by further Most Favored Nation deals, and continued positive momentum in biotechnology. The fund delivered strong results with positive contributions from all subsectors, led by biotechnology and medical technology. Exposure to biotechnology was increased, financed by reduced exposure to pharmaceuticals. We believe the […]
Monthly comment (Sep 2025): Signs of increased optimism
Summary September was dominated by US politics and rising investor appetite in the healthcare sector. The US government shut down after Democrats demanded an extension of health insurance marketplace subsidies in the budget negotiations. At the same time, an initial MFN agreement brought greater clarity on drug pricing and tariffs. The fund’s biotechnology segment performed […]
Monthly comment (June 25): A month of contrasts
Summary Positive clinical data and M&A activity picked up in the sector. We saw more signs that the deal window may be reopening. The Senate version of the reconciliation bill included deeper cuts to Medicaid than the House version. The fund had strong results in dollar terms and relative to the broader healthcare sector but […]
Rhenman & Partners strengthens investment team – hires additional biopharma PM
Rhenman & Partners hires Camilla Oxhamre Cruse as Portfolio Manager – biotech and pharma. She will have a particular focus on companies within pharmaceutical development. Camilla joins Rhenman & Partners’ investment team of four people, all based in their Stockholm office. Camilla has a master’s degree in biochemistry from Lund University (Lund) and obtained a […]
Rhenman & Partners celebrates 15 years
On 21 May Rhenman & Partners took the opportunity to celebrate 15 successful years by inviting guests to a seminar in Stockholm. The article below is a summary of the day and captures the key messages from each presentation. Click here to read or download the article as a PDF. Rhenman & Partners celebrates […]
Susanna Urdmark included in The Hedge Fund Journal’s “50 Leading Women in Hedge Funds 2021”
All of us at Rhenman & Partners are very proud and happy to see Susanna Urdmark included in The Hedge Fund Journal’s “50 Leading Women in Hedge Funds 2021”. This is a fantastic recognition of her expertise, dedication and long-standing focus on the healthcare sector. Congratulations Susanna and all the women included in this year’s […]